Live Breaking News & Updates on Grifols Group

Stay updated with breaking news from Grifols group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Biotest increased sales by 83.6% to Euro 215.2 million in first quarter 2024

EQS-News: Biotest AG

/ Key word: Quarter Results

Biotest increased sales by 83.6% to Euro 215.2 million in first quarter 2024

07.05.2024 / 09:00 CET/CEST

The issuer is. ....

Czech Republic , Comunidad Autonoma De Cataluna , United States , United Kingdom , Monika Baumann Buttkereit , Dirk Neum , Grifols Group , Drug Administration , Biotest Group , Biotest Next Level , Biologics License Application , Primary Immunodeficiencies , Biotest Next , Quarterly Reports , Prime Standard , Monika Baumann ,

Biotest AG increased sales by 32% in the financial year 2023

EQS-News: Biotest AG

/ Key word: Annual Results

Biotest AG increased sales by 32% in the financial year 2023

28.03.2024 / 12:38 CET/CEST

The issuer is solely. ....

Comunidad Autonoma De Cataluna , United States , Monika Baumann Buttkereit , Dirk Neum , Grifols Group , Biotest Group , Drug Administration , Biotest Next Level , Biologics License Application , Pre License Inspection , Prime Standard , Monika Baumann ,

EQS-News: Biotest achieves EBIT forecast for 2023

EQS-News: Biotest AG / Key word(s): Preliminary Results Biotest achieves EBIT forecast for 2023 29.02.2024 / 07:45 CE. ....

Comunidad Autonoma De Cataluna , Dirk Neum , Monika Buttkereit , Biotest Group , Grifols Group , Annual General Meeting , Management Board , Supervisory Board , Prime Standard ,

Biotest achieves EBIT forecast for 2023

EQS-News: Biotest AG

/ Key word: Preliminary Results

Biotest achieves EBIT forecast for 2023

29.02.2024 / 07:45 CET/CEST

The issuer is solely responsible for the. ....

Comunidad Autonoma De Cataluna , Dirk Neum , Monika Buttkereit , Grifols Group , Biotest Group , Annual General Meeting , Management Board , Supervisory Board , Prime Standard ,

Grifols announces positive topline phase 3 fibrinogen clinical trial results

In the AdFIrst study, Biotest s fibrinogen concentrate (FC), BT524, met the primary endpoint, demonstrating its effectiveness in treating acquired. ....

Comunidad Autonoma De Cataluna , United States , Ig Yimmugo , Victor Grifols Deu , Biotest Adfirst , Media Press Office , Grifols Group , Investors Relations Department Sustainability , Spanish Stock Exchange , Grifols Chief Scientific Innovation , Grifols Chief Operating , Adjusted Fibrinogen Replacement Strategy , North America , Middle East , Mercado Continuo , Royal Legislative Decree , Securities Market Law , Royal Decree Law , Royal Decree ,